Nasal Spray Firm Aims to Challenge FTC's Regulation of Health Assertions
The company Xlear attracted attention from the FTC after marketing its nasal spray as a preventive measure against COVID. Although the Trump administration later chose to drop the lawsuit, Xlear remains adamant about seeking a court ruling.
Amid the surge of the COVID-19 crisis, Xlear pushed its saline nasal spray to the forefront as people searched for new ways to shield themselves. Xlear leveraged scientific studies in its advertising, claiming the spray's composition could stop viruses from adhering to nasal tissues. This argument was part of their broader strategy, promoting the spray as a component of a multi-faceted defense against COVID-19.
Confrontation with the FTC
By 2021, the FTC had voted across party lines to take legal action against Xlear, accusing it of making health claims unsupported by sufficient evidence. The Commission argued that Xlear significantly exaggerated the results and relevance of scientific data in their promotional material. Despite the Trump administration's Justice Department later advocating for the case's dismissal, without stating reasons, Xlear pursued litigation.
Xlear's lawsuit arises as there's upheaval in federal processes concerning both scientific and administrative governance. In recent years, the federal health landscape has been undergoing significant changes, potentially shifting the balance towards alternative health approaches.
Innovation vs. Regulation
Reflecting broader tensions in health regulation, Xlear’s legal team suggests the firm doesn't seek to dilute standards but demands a fair legal benchmark for health claim assessments. They argue that recent changes to legal precedent, affecting how courts defer to federal agency expertise, support their position. Their contention centers on ensuring legal compliance, not merely swift adherence to FTC’s evolving standards.
From Xlear's perspective, the FTC has set arbitrary criteria for what constitutes acceptable evidence in substantiating health claims. Robust proof according to FTC guidance primarily involves Randomized Controlled Trials (RCTs), considered the gold standard in research. However, Xlear challenges whether most smaller enterprises can meet such demanding requirements.
Broad Implications of the Legal Battle
Xlear's legal efforts also aim to secure freedom to advertise another product believed to be a fluoride alternative. Fluoride, a common mineral, is frequently discussed in both scientific and pop culture circles, sometimes controversially.
Xlear’s counsel clarifies that even a successful lawsuit doesn’t imply a free-for-all in marketing practices. The FTC would retain its authority to address false or misleading claims, albeit with more transparency in its criteria. Housman emphasizes that genuine, misleading advertisements would remain under scrutiny, with the potential for private lawsuits acting as a deterrent against spurious claims.



Leave a Reply